Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment

Weiss, Lina; Wustmann, Kerstin Brigitte; Semmo, Mariam; Schwerzmann, Markus; Semmo, Nasser (2018). Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment. Case reports in gastroenterology, 12(1), pp. 92-98. Karger 10.1159/000486951

Preview

Text Amiodaron-HCV Paper.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (644kB) | Preview

A sofosbuvir/ledipasvir combination is part of a first-line treatment of hepatitis C. However, in patients concurrently treated with amiodarone, cardiac side effects have been described, resulting in an official warning in 2015 by the American Food and Drug Administration and the European Medicines Agency when combining those substances. This deprived numerous hepatitis C patients with concurrent cardiovascular problems of receiving this highly effective treatment. Here we present a treatment alternative with an elbasvir/grazoprevir regimen, based on our successful treatment of a patient under concurrent amiodarone therapy. Our observations indicate that patients treated with amiodarone can finally benefit from effective antiviral therapy.

Interest & Impact

Downloads

196 since deposited on 23 Apr 2018
17 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item